The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence

Research output: Contribution to journalArticle

Abstract

Antimuscarinic agents are the most commonly used treatments for overactive bladder (OAB) syndrome where they reduce urgency, frequency, and urge incontinence. Despite few studies investigating the effects of antimuscarinic agents on mixed urinary incontinence (MUI), awareness is increasing about their value as first-line treatments for patients with MUI (combination of OAB wet and stress urinary incontinence). Evidence suggests that they are as effective in patients with urgency-predominant MUI as they are in OAB, resulting in significant reductions in urgency episodes, urinary frequency, and incontinence.

Original languageEnglish
Pages (from-to)849-853
Number of pages5
JournalEuropean Urology, Supplements
Volume5
Issue number16
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Muscarinic Antagonists
Urinary Incontinence
Overactive Urinary Bladder
Urge Urinary Incontinence
Stress Urinary Incontinence
Therapeutics

Keywords

  • Antimuscarinic agents
  • Overactive bladder syndrome (OAB)
  • Solifenacin
  • Stress incontinence
  • Tolterodine

ASJC Scopus subject areas

  • Urology

Cite this

The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence. / Salvatore, Stefano.

In: European Urology, Supplements, Vol. 5, No. 16, 10.2006, p. 849-853.

Research output: Contribution to journalArticle

@article{c92bad759d1747c39921889ba9f55980,
title = "The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence",
abstract = "Antimuscarinic agents are the most commonly used treatments for overactive bladder (OAB) syndrome where they reduce urgency, frequency, and urge incontinence. Despite few studies investigating the effects of antimuscarinic agents on mixed urinary incontinence (MUI), awareness is increasing about their value as first-line treatments for patients with MUI (combination of OAB wet and stress urinary incontinence). Evidence suggests that they are as effective in patients with urgency-predominant MUI as they are in OAB, resulting in significant reductions in urgency episodes, urinary frequency, and incontinence.",
keywords = "Antimuscarinic agents, Overactive bladder syndrome (OAB), Solifenacin, Stress incontinence, Tolterodine",
author = "Stefano Salvatore",
year = "2006",
month = "10",
doi = "10.1016/j.eursup.2006.07.014",
language = "English",
volume = "5",
pages = "849--853",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "16",

}

TY - JOUR

T1 - The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence

AU - Salvatore, Stefano

PY - 2006/10

Y1 - 2006/10

N2 - Antimuscarinic agents are the most commonly used treatments for overactive bladder (OAB) syndrome where they reduce urgency, frequency, and urge incontinence. Despite few studies investigating the effects of antimuscarinic agents on mixed urinary incontinence (MUI), awareness is increasing about their value as first-line treatments for patients with MUI (combination of OAB wet and stress urinary incontinence). Evidence suggests that they are as effective in patients with urgency-predominant MUI as they are in OAB, resulting in significant reductions in urgency episodes, urinary frequency, and incontinence.

AB - Antimuscarinic agents are the most commonly used treatments for overactive bladder (OAB) syndrome where they reduce urgency, frequency, and urge incontinence. Despite few studies investigating the effects of antimuscarinic agents on mixed urinary incontinence (MUI), awareness is increasing about their value as first-line treatments for patients with MUI (combination of OAB wet and stress urinary incontinence). Evidence suggests that they are as effective in patients with urgency-predominant MUI as they are in OAB, resulting in significant reductions in urgency episodes, urinary frequency, and incontinence.

KW - Antimuscarinic agents

KW - Overactive bladder syndrome (OAB)

KW - Solifenacin

KW - Stress incontinence

KW - Tolterodine

UR - http://www.scopus.com/inward/record.url?scp=33748193353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748193353&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2006.07.014

DO - 10.1016/j.eursup.2006.07.014

M3 - Article

AN - SCOPUS:33748193353

VL - 5

SP - 849

EP - 853

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 16

ER -